荧光标记蛋白

近年来，流式细胞术被广泛应用于生物药研发和生产的各个环节。荧光标记蛋白作为流式检测的首选试剂，因其预先标记了荧光素基团，可通过一步染色完成检测，既简化了检测流程、节省了检测时间，又避免了因使用二抗而产生的非特异背景。然而，高质量荧光标记蛋白的生产面临着诸多难题，如标记后蛋白活性难以维持、产品的批间一致性难以控制等，目前市场上少有高质量荧光标记蛋白可供购买。

ACROBiosystems作为专注于生物药研发领域的蛋白供应商，利用专业的蛋白研发及标记平台、稳定株开发平台和流式细胞分析平台，开发了一系列包括FITC标记和PE标记的靶点蛋白，适用于基于流式细胞术的分析试验，如CAR阳性表达率的检测和流式细胞术筛选抗体候选药物等。

产品特色

标记后蛋白活性经流式细胞术验证
可提供配套流式检测protocol供参考
标记前后活性保持一致
高批间一致性

应用案例

流式细胞术检测Anti-CD19 CAR阳性表达率

FACS Analysis of Anti-CD19 CAR Expression
: 293 cells were transfected with anti-CD19-scFv and RFP tag. 2e5 of the cells were stained with B. FITC-Labeled Human CD19 (20-291), Fc Tag (Cat. No. CD9-HF251, 10 μg/ml) and C. FITC-labeled protein control. A. Nin-transfected 293 cells and C. FITC-labeled protein control were used as negative control. RFP was used to evaluate CAR (anti-CD19-scFv) expression and FITC was used to evaluate the binding activity of FITC-Labeled Human CD19 (20-291), Fc Tag (Cat. No. CD9-HF251) (QC tested).; Protocol

基于流式细胞术的配体结合试验

: Flow Cytometry assay shows that PE-Labeled Human PD-1, Fc Tag, His Tag (recommended for neutralizing assay) (Cat. No. PD1-HP2F2) can bind to 293T cells overexpressing human PD-L1. 1μl stock solution per million cells (QC tested).; Protocol

基于流式细胞术的中和抗体筛选试验

: FACS analysis shows that the binding of PE-Labeled Human PD-1, Fc Tag, His Tag (recommended for neutralizing assay) (Cat.No.PD1-HP2F2) to 293T overexpressing PD-L1 was inhibited by increasing concentration of neutralizing antihuman PD-L1 antibody. The IC50 is 0.29 μg/ml (QC tested).; Protocol

质控

高批间一致性

: Binding activity of three different lots of FITC-labeled Human MSLN, Fc Tag was evaluated in the above FACS analysis against Anti-MSLN CAR-293 cells. The result shows very high batch-to-batch consistency.

: Binding activity of three different lots of FITC-labeled Human MSLN, Fc Tag was evaluated in the above ELISA analysis against Anti-MSLN Antibody. The result shows very high batch-to-batch consistency.

标记前后活性保持一致

: Binding activity of the Human MSLN, Fc Tag before and after FITC labeling was evaluated in the above ELISA analysis. The result shows that FITC-Labeled and Unconjugated Human MSLN, Fc Tag have almost the same level of binding activity.

稳定性好

: Binding activity of FITC-labeled Human MSLN, Fc Tag was evaluated in the above FACS analysis against Anti-MSLN CAR-293 cells. The result shows that the FITC-labeled Human MSLN is stable at 37℃ for 24 hours without performance reduction.

: Binding activity of FITC-labeled Human MSLN, Fc Tag was evaluated in the above FACS analysis against Anti-MSLN CAR-293 cells. The result shows that the FITC-labeled Human MSLN is stable within three freeze-thaw cycles without performance reduction.

产品列表

PE Labeled Protein

Molecule	Cat. No.	Species	Product Description	Host
SIRP alpha	SIA-HP252	Human	PE-Labeled Human SIRP alpha, Fc Tag (recommended for neutralizing assay)	HEK293
PD-1	PD1-HP2F2	Human	PE-Labeled Human PD-1, Fc Tag, His Tag (recommended for neutralizing assay)	HEK293
Mesothelin	MSN-HP223	Human	PE-Labeled Human Mesothelin (296-580)	HEK293

FITC Labeled Protein

Molecule	Cat. No.	Species	Product Description	Host
Mesothelin	MSN-HF25x	Human	FITC-Labeled Human Mesothelin (296-580), Fc Tag	HEK293
	MSN-HF223	Human	PE-Labeled Human Mesothelin (296-580)	HEK293
	MSN-HF253	Human	FITC-Labeled Human Mesothelin (296-580), Fc Tag	HEK293
CD30	CD0-HF2H3	Human	FITC-Labeled Human CD30, His Tag	HEK293
SLAMF7	SL7-HF2H7	Human	FITC-Labeled Human SLAMF7, His Tag	HEK293
BCMA	BCA-HF2H1	Human	FITC-Labeled Human BCMA, His Tag	HEK293
BCMA	BCA-HF254	Human	FITC-Labeled Human BCMA, Fc Tag	HEK293
Siglec-2	SI2-HF2H6	Human	FITC-Labeled Human Siglec-2	HEK293
CD19	CD9-HF251	Human	FITC-Labeled Human CD19 (20-291), Fc Tag	HEK293
CD19	CD9-HF2H2	Human	FITC-Labeled Human CD19 (20-291)	HEK293
Glypican 3	GP3-HF258	Human	FITC-Labeled Human Glypican 3, Fc Tag	HEK293
Glypican 3	GP3-HF2H1	Human	FITC-Labeled Human Glypican 3, His Tag	HEK293
Protein L	RPL-PF141	-	FITC-Labeled Recombinant Protein L	E.coli
BAFF	BAF-HF268	Human	FITC-Labeled Human BAFF / TNFSF13B / CD257 Protein, Fc Tag	HEK293

会议日历

会议一览

新闻订阅

在线留言

消息提示